Your browser doesn't support javascript.
loading
Neutralizing antibodies from prior exposure to dengue virus negatively correlate with viremia on re-infection.
Anantharaj, Anbalagan; Agrawal, Tanvi; Shashi, Pooja Kumari; Tripathi, Alok; Kumar, Parveen; Khan, Imran; Pareek, Madhu; Singh, Balwant; Pattabiraman, Chitra; Kumar, Saurabh; Pandey, Rajesh; Chandele, Anmol; Lodha, Rakesh; Whitehead, Stephen S; Medigeshi, Guruprasad R.
Affiliation
  • Anantharaj A; Bioassay laboratory and Clinical and Cellular Virology lab, Translational Health Science and Technology Institute, Faridabad, Haryana, India.
  • Agrawal T; Bioassay laboratory and Clinical and Cellular Virology lab, Translational Health Science and Technology Institute, Faridabad, Haryana, India.
  • Shashi PK; Bioassay laboratory and Clinical and Cellular Virology lab, Translational Health Science and Technology Institute, Faridabad, Haryana, India.
  • Tripathi A; Bioassay laboratory and Clinical and Cellular Virology lab, Translational Health Science and Technology Institute, Faridabad, Haryana, India.
  • Kumar P; Bioassay laboratory and Clinical and Cellular Virology lab, Translational Health Science and Technology Institute, Faridabad, Haryana, India.
  • Khan I; Bioassay laboratory and Clinical and Cellular Virology lab, Translational Health Science and Technology Institute, Faridabad, Haryana, India.
  • Pareek M; Bioassay laboratory and Clinical and Cellular Virology lab, Translational Health Science and Technology Institute, Faridabad, Haryana, India.
  • Singh B; Bioassay laboratory and Clinical and Cellular Virology lab, Translational Health Science and Technology Institute, Faridabad, Haryana, India.
  • Pattabiraman C; Independent researcher, Bengaluru, India.
  • Kumar S; Bioassay laboratory and Clinical and Cellular Virology lab, Translational Health Science and Technology Institute, Faridabad, Haryana, India.
  • Pandey R; INtegrative GENomics of HOst-PathogEn (INGEN-HOPE) laboratory, Division of Immunology and Infectious Disease Biology, CSIR-Institute of Genomics and Integrative Biology, Delhi, India.
  • Chandele A; ICGEB-Emory Vaccine Center, International Center for Genetic Engineering and Biotechnology, Aruna Asaf Ali Marg, New Delhi, India.
  • Lodha R; Department of Pediatrics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India.
  • Whitehead SS; Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Medigeshi GR; Bioassay laboratory and Clinical and Cellular Virology lab, Translational Health Science and Technology Institute, Faridabad, Haryana, India. gmedigeshi@thsti.res.in.
Commun Med (Lond) ; 3(1): 148, 2023 Oct 19.
Article in En | MEDLINE | ID: mdl-37857747
India is one of the hotspots of dengue infection. The objective of the study was to assess whether having previous exposure to dengue virus could influence how the body will respond to repeat infections with dengue virus. Here, we analysed samples from febrile patients to measure the amount of dengue virus genetic material in the blood, the type of virus and the amount of antibodies, which are proteins produced by the host in response to dengue virus infection. The majority of patient samples demonstrated the capability to restrict all four types of dengue virus in circulation within the country, but reduced capacity to restrict when it comes to international dengue virus types. These data will help to inform future dengue vaccine design and clinical studies in India.

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Commun Med (Lond) Year: 2023 Document type: Article Affiliation country: India

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Commun Med (Lond) Year: 2023 Document type: Article Affiliation country: India